Redeye provides an update following Neola Medical’s Q1 2026 report. The report was relatively undramatic, with slightly higher costs than expected. The focus remains on the upcoming studies in 2027, which we see as the main near-term trigger for the share. In this update, we make minor fine-tuning adjustments to our sales and OPEX assumptions, resulting in a slightly revised fair value range.
LÄS MER
